Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Post by dwyomingon Jul 17, 2009 2:02pm
662 Views
Post# 16146501

Financing News

Financing News

iCo Therapeutics completes $475,000 financing

2009-07-16 16:32 ET - News Release

Dr. John Clement reports

ICO THERAPEUTICS CLOSES NON-BROKERED PRIVATE PLACEMENT

ICo Therapeutics Inc. has completed a non-brokered private placement in the amount of $475,000 through the issuance of 1,187,500 common shares in the capital of the company at a subscription price of 40 cents per share. The company intends to use the net proceeds for working capital and general corporate purposes.

A finder's fee of 7 per cent will be payable to certain arm's-length third parties with respect to a portion of the private placement. All securities issued in the private placement are subject to a four-month hold period. The private placement is subject to regulatory approval, including the approval of the TSX Venture Exchange.

We seek Safe Harbor.

Bullboard Posts